South Carolina is currently home to 1159 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Columbia and Spartanburg. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
TRIAD Appendicitis Decision-making Surveys
NCT05887414
Recruiting
While appendectomy has been the main treatment of appendicitis for over 100 years, recent European studies found that, at least among highly selected patients, antibiotics alone can be an effective alternative. Surgeons and patients alike have a difficult time deciding if surgery or antibiotics are the best choice to treat appendicitis. The goal of the TRIAD is to evaluate the patients who are a part of the TRIAD implementation program and assess satisfaction and decisional regret for patients w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Appendicitis
Register for Updates
Connect Through PLAY: A Staff-based Physical Activity Intervention for Middle School Youth
NCT03732144
Recruiting
The overall goal of the Connect Through Positive Leisure Activities for Youth (PLAY) Project is to improve staff capacity for implementing effective physical activity (PA) programming within middle school after school programs serving high-risk youth. All components of the 'Connect' intervention (health promotion initiative, comprehensive training, and tailored physical activity curriculum) aim to support staff cohesion, motivation and efficacy in facilitating a PA context that supports youth so... Read More
Gender:
ALL
Ages:
Between 9 years and 16 years
Trial Updated:
05/08/2023
Locations: University of South Carolina, Columbia, South Carolina
Conditions: Physical Activity, Obesity Prevention
Register for Updates
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
NCT03945162
Recruiting
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Site 02-006 - Carolina Urologic Research Center, Myrtle Beach, South Carolina
Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Register for Updates
Rett Syndrome Registry
NCT05432349
Recruiting
The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett s... Read More
Gender:
ALL
Ages:
Between 0 years and 99 years
Trial Updated:
01/09/2023
Locations: Greenwood Genetic Center, Greenwood, South Carolina
Conditions: Rett Syndrome, Rett Syndrome, Atypical, Genetic Disease, Genetic Diseases, X-Linked, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Neurologic Disorder, Neurodevelopmental Disorders, Nervous System Diseases
Register for Updates
Universal Germline Testing in the Community
NCT05416710
Recruiting
This study seeks to enroll participants who have a diagnosis of a solid tumor cancer and are willing to undergo germline genetic testing for cancer risk. At baseline, patients will be asked to provide 2 types of blood samples: 1 tube for clinical genetic testing and 2 tubes for future research use. A tumor sample from a previous resection or biopsy will also be obtained and sent to the sponsor. The clinician will be asked to provide relevant medical history and demographic information to the spo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2022
Locations: Carolina Blood and Cancer Care Associates, PA', Rock Hill, South Carolina
Conditions: Cancer, Solid Tumor, Solid Tumor, Adult
Register for Updates
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
NCT03540771
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: End Stage Liver Disease
Register for Updates
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
NCT05149300
Recruiting
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration The secondary objectives of the study are: To assess the safety and tolerability of SC or single administration of casirivimab+imdevimab To assess the occurrence of grade ≥3 injection site reactions and grade ≥3 hypersensitivity reactions, in participants treated with SC doses of casirivimab+imdevimab To assess the immunogenicity o... Read More
Gender:
All
Ages:
12 years and below
Trial Updated:
12/06/2021
Locations: Coastal Pediatric Research, Charleston, South Carolina
Conditions: COVID-19
Register for Updates